4F-4PP
Pharmaceutical compound
From Wikipedia, the free encyclopedia
4F-4PP, or 4F4PP, also known as 4-(4-fluorobenzoyl)-1-(4-phenylbutyl)piperidine, is a selective serotonin 5-HT2A receptor antagonist which is used in scientific research.[1][2][3]
- None
- 120357-05-3
144734-36-1 (oxalate)
| Clinical data | |
|---|---|
| Other names | 4F4PP; FPPO; 4-PBFBP; FBP; 4-(4-Fluorobenzoyl)-1-(4-phenylbutyl)piperidine; N-(4-Phenylbutyl)-4-(4-fluorobenzoyl)piperidine |
| Drug class | Serotonin 5-HT2A receptor antagonist |
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H26FNO |
| Molar mass | 339.454 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pharmacology
4F-4PP shows high affinity for the serotonin 5-HT2A receptor (Ki = 5.3 nM) and 120-fold lower affinity for the serotonin 5-HT2C receptor (Ki = 620 nM).[1][3] For comparison, ketanserin showed only 14-fold higher affinity for the serotonin 5-HT2A receptor over the serotonin 5-HT2C receptor in the same study.[1] In a functional assay, 4F-4PP was 204-fold more potent as a serotonin 5-HT2A receptor antagonist than as a serotonin 5-HT2C receptor antagonist.[2] The drug does not appear to block the serotonin 5-HT2B receptor.[4] It showed limited and non-significant effects on the oxytocin and vasopressin secretion induced by the serotonin 5-HT2A and 5-HT2C receptor agonist and serotonergic psychedelic DOI in rodents.[3]
Chemistry
Analogues
A radiolabeled isotopologue for use in positron emission tomography (PET) imaging has been described.[5]
History
4F-4PP first described in the scientific literature by 1992.[1] It is an analogue of and was derived via structural modification of ketanserin.[1]